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Abstract
Background: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/
CT) has become an established method for detecting hypermetabolic sites of known and occult disease and is
widely used in oncology surgical planning. Intraoperatively, it is often difficult to localize tumors and verify
complete resection of tumors that have been previously detected on diagnostic PET/CT at the time of the original
evaluation of the cancer patient. Therefore, we propose an innovative approach for intraoperative tumor
localization and verification of complete tumor resection utilizing 18F-FDG for perioperative PET/CT imaging and
intraoperative gamma probe detection.
Methods: Two breast cancer patients were evaluated. 18F-FDG was administered and PET/CT was acquired
immediately prior to surgery. Intraoperatively, tumors were localized and resected with the assistance of a
handheld gamma probe. Resected tumors were scanned with specimen PET/CT prior to pathologic processing.
Shortly after the surgical procedure, patients were re-imaged with PET/CT utilizing the same preoperatively
administered 18F-FDG dose.
Results: One patient had primary carcinoma of breast and a metastatic axillary lymph node. The second patient
had a solitary metastatic liver lesion. In both cases, preoperative PET/CT verified these findings and demonstrated
no additional suspicious hypermetabolic lesions. Furthermore, intraoperative gamma probe detection, specimen
PET/CT, and postoperative PET/CT verified complete resection of the hypermetabolic lesions.
Conclusion: Immediate preoperative and postoperative PET/CT imaging, utilizing the same 18F-FDG injection
dose, is feasible and image quality is acceptable. Such perioperative PET/CT imaging, along with intraoperative
gamma probe detection and specimen PET/CT, can be used to verify complete tumor resection. This innovative
approach demonstrates promise for assisting the oncologic surgeon in localizing and verifying resection of 18F-
FDG positive tumors and may ultimately positively impact upon long-term patient outcomes.
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Background
For many cancers, the risk of recurrence remains decep-
tively elevated despite presumption of complete resection
at the time of initial surgical management. This implies
that occult disease may remain undetected at the time of
surgery and resultantly may not be resected by the stand-
ard surgical approaches. In this regard, diagnostic 18F-
fluorodeoxyglucose (18F-FDG) positron emission tomog-
raphy/computed tomography (PET/CT) imaging has
become an established method for detecting sites of
occult disease in oncology and is widely used in medical
and surgical planning of cancer patients.
Breast cancer remains the leading cause of newly diag-
nosed cases of cancer and the second leading cause of can-
cer deaths among women in the United States [1]. The
current standard of care for surgical management of breast
cancer is resection of the primary breast tumor and evalu-
ation of the axillary lymph nodes, which includes axillary
lymph node dissection in cases of documented nodal
involvement [2]. Subsequent appropriately selected adju-
vant therapies (including cytotoxic systemic chemother-
apy, anti-estrogen therapy, immunotherapy, and
radiation therapy) are important adjuncts to the overall
management scheme. Despite these best efforts, relative
survival rates for women diagnosed with breast cancer are
88% at five years, 80% at 10 years, 71% at 15 years, and
63% at 20 years [3].
18F-FDG PET/CT imaging has demonstrated reasonably
good success in detecting locally advanced breast cancer,
regional lymph node involvement, and distant metastases
[4-8]. The current practice for PET/CT imaging is that of
preoperative image acquisition, usually taking place at the
time of the original evaluation of the cancer patient, for
detecting all potential sites of regional and distant meta-
static disease. Nevertheless, it is often difficult to intraop-
eratively localize tumors that have been previously
detected on PET/CT imaging done at the time of the orig-
inal evaluation of the cancer patient. While this current
practice of preoperative image acquisition at the time of
the original evaluation provides a static roadmap for guid-
ing the surgical approach of the oncologic surgeon, it does
not provide vital real-time intraoperative information on
tumor localization and immediate verification of com-
plete tumor resection. Therefore, development and refine-
ment of innovative approaches for perioperatively
detecting and intraoperatively directing the oncologic sur-
geon for the intraoperative identification and removal of
all sites of disease may ultimately translate into improved
long-term patient outcomes.
In the current report, we describe an innovative combined
perioperative and intraoperative approach for the locali-
zation of tumors and verification of complete tumor
resection utilizing single-dose 18F-FDG, perioperative
PET/CT imaging, and intraoperative handheld gamma
probe detection in two very distinctive cases of advanced
breast cancer.
Methods
Patients
Two patients with potentially resectable metastatic breast
cancer that were evaluated by the surgical oncology service
at the Arthur G. James Cancer Hospital and Richard J.
Solove Research Institution of The Ohio State University
were asked to participate in this study. Written informed
consent was obtained from each patient after all aspects of
the proposed imaging and detection schema were fully
discussed with them. One patient had locally advanced
breast cancer, involving both her left breast and her left
axillary lymph nodes. The other patient had a history of
breast cancer with a solitary metastasis in the left lobe of
her liver. Both patients underwent standard preoperative
testing, including diagnostic CT scans at the time of their
original evaluation, for detecting all potential sites of
disease.
18F-FDG PET/CT Imaging and Handheld Gamma Probe 
Detection Schema
Each patient underwent a preoperative injection of 18F-
FDG on the same day as surgery. A dose of 14 to 19 mCi
18F-FDG was injected intravenously into a peripheral vein
of each patient approximately 120 minutes prior to the
anticipated time of surgery. At approximately 75 minutes
post-injection of 18F-FDG, a preoperative clinical PET/CT
scan was obtained (Siemens Biograph 16 PET/CT,
Knoxville, TN). PET imaging was immediately preceded
by transmission CT (for attenuation correction and ana-
tomic correlation purposes) and was obtained from the
base of the skull to the mid thighs. Bed positions were
scanned for 3 minutes each, moving the patient through
the scanner in a craniocaudad direction. Once the preop-
erative clinical PET/CT scan was acquired, images were
reviewed by the oncologic surgeon and the nuclear
medicine physician.
Intraoperatively, all potential sites of tumor were local-
ized via standard visualization and palpation. Addition-
ally, tumor was localized with the assistance of a
handheld gamma probe (Neoprobe neo2000 unit, Neo-
probe Corporation, Dublin, Ohio). The 18F-FDG dose
from the preoperative clinical PET/CT scan provided radi-
oactivity that was detected intraoperatively by the hand-
held gamma probe. Gamma counts of blood pool and
normal background tissue were recorded along with
gamma counts from metabolically active tumor. The
handheld gamma probe was used to assist in resection of
the tumor and in assessment of surgical margins of resec-
tion. Three sigma criteria was used in determining theWorld Journal of Surgical Oncology 2007, 5:143 http://www.wjso.com/content/5/1/143
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threshold for positivity of tissue for the gamma probe. The
three sigma criteria defines the threshold for positivity of
tissue as the average background activity in normal tissue
plus three times the square root of the average background
activity. This technique has been used with success
in intraoperative gamma probe detection of other
radioactive tracers [9].
Once resected, the surgical specimen was transported to
the radiology department and placed on top of a paraffin
block. Digital photographs of the specimen were obtained
for visual correlation of specimen placement on the paraf-
fin block. A two bed position ten minute specimen PET/
CT scan was then performed on the surgical specimen.
Images were processed and reviewed for quality and pres-
ence or absence of hypermetabolic foci that were origi-
nally noted in the preoperative clinical PET/CT scan. This
process allowed for intraoperative verification of com-
plete tumor resection, as well as for potentially marking
concerning areas of hypermetabolic activity that might
require special attention from the pathologist. The speci-
men was then transported back to the operating room in
order to be sent to and processed by surgical pathology for
standard pathologic evaluation.
Postoperatively, each patient was taken to the post-
anesthesia care unit (PACU) for standard postoperative
recovery. After postoperative standard stabilization and
recovery (at approximately 120 minutes after the comple-
tion of the surgical procedure), each patient was trans-
ported to the radiology department and was re-imaged
with a postoperative PET/CT scan. The postoperative PET/
CT scan was done utilizing the same preoperative clinical
PET/CT18F-FDG dose. No additional 18F-FDG was admin-
istered. The postoperative PET/CT scan was obtained in a
similar fashion as that of the preoperative clinical PET/CT
scan, except that only the areas of the body with abnormal
hypermetabolic foci on the preoperative PET/CT images
were targeted for the field of imaging. Bed positions were
scanned for 10 minutes each on the postoperative PET/CT
scan compared to 3 minutes on the preoperative clinical
PET/CT scan. The postoperative PET/CT scan allowed for
re-verification of completeness of tumor resection and for
assessment for evidence of residual disease.
Results
Patient 1
A 72 year-old Caucasian female presented with a palpable
left breast mass. Clinical exam revealed a 4 cm palpable
mass in the left subareolar region and a 2.5 cm palpable
left axillary mass. These findings were confirmed on mam-
mography and ultrasound. An ultrasound-guided 14-
gauge core biopsy was performed to both the left breast
mass and the left axillary mass. Both core biopsies
revealed poorly differentiated invasive ductal carcinoma.
CT scan of the chest, abdomen, and pelvis showed a left
breast mass, a left axillary mass, generalized atheroscle-
rotic disease, and several subcentimeter hepatic cysts, but
no evidence of intrathoracic, intraabdominal, or intrapel-
vic metastatic disease. Whole body bone scan showed no
osseous metastatic lesions.
On the day of surgery, the preoperative clinical PET/CT
demonstrated a solitary hypermetabolic lesion within the
left breast with a peak SUV of 14.2 and a solitary hyper-
metabolic lesion in the left axilla with a peak SUV of 6.6
(Figure 1).
The patient was subsequently taken to the operating
room. Intraoperative verification of tumor location
within the left breast and left axilla was performed by pal-
pation and by handheld gamma probe detection. The
patient then underwent a left modified radical mastec-
tomy, including a standard left axillary level I and II
lymph node dissection. Post-resection, the surgical bed
was again evaluated by handheld gamma probe detection
and was found to have no activity above background.
The entire resected specimen was re-imaged by specimen
PET/CT and revealed two hypermetabolic foci, represent-
ing the primary breast tumor and the solitary axillary
metastasis (Figure 2A and 2B).
Preoperative PET maximum intensity projection in the lateral  projection view (A) and cross sectional fused PET/CT images  (B) Figure 1
Preoperative PET maximum intensity projection in the lateral 
projection view (A) and cross sectional fused PET/CT images 
(B). The preoperative PET/CT scan revealed two hypermeta-
bolic foci, representing the left breast primary tumor and the 
solitary left axillary metastasis.World Journal of Surgical Oncology 2007, 5:143 http://www.wjso.com/content/5/1/143
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Postoperatively, the patient recovered uneventfully in
the PACU. She was subsequently taken to the radiology
department and re-imaged with PET/CT scan, demon-
strating complete resection of the primary breast tumor
and solitary axillary metastasis, and no residual hypermet-
abolic foci were identified (Figure 2C).
Pathology revealed a 4.5 cm poorly differentiated invasive
ductal carcinoma with lymphovascular invasion and neg-
ative surgical margins (all greater than 1 cm). Only one of
23 left axillary lymph nodes was involved with metastatic
disease (representing the lowest lying lymph node within
the left axillary dissection portion of the specimen). This
solitary lymph node metastasis measured 2.4 cm in size
and there was no evidence of extranodal extension. The
primary breast tumor was negative for estrogen receptors
(ER) and negative for progesterone receptors (PR).
The primary breast tumor was negative for Her2neu by
both immunohistochemistry and fluorescence in-situ
hybridization (FISH).
Patient 2
A 52 year-old Caucasian female was originally diagnosed
with poorly differentiated invasive ductal carcinoma
(pT1c, negative for ER and PR, positive for Her2neu by
immunohistochemistry, pN0) of her left breast six years
prior to her current presentation. She underwent a left
breast lumpectomy, left axillary lymph node dissection,
four cycles of postoperative Adriamycin and Cytoxan
chemotherapy, and postoperative radiation therapy.
Three years prior to her current presentation, she devel-
oped numerous liver metastases and a markedly elevated
CA 15-3 at 952 U/mL (normal range 9 to 42). She received
six months of Taxotere and Herceptin. Her CA 15-3
decreased into the range of 35 to 40 U/mL and her numer-
ous liver metastases regressed. Due to Taxotere toxicity,
she was thereafter maintained on Herceptin alone for the
next 18 months. However, 17 months prior to her current
presentation, CT scan of the abdomen demonstrated a
new left hepatic lesion and brain MRI revealed a solitary 9
× 5 mm enhancing left cerebellar lesion. Gamma knife
radiosurgery was successfully performed to the left cere-
bellar lesion. She was subsequently maintained on Her-
ceptin until 13 months prior to her current presentation
when she was noted to have progression of the solitary left
hepatic lesion. At that time, she was restarted on combi-
nation Taxotere and Herceptin. She did well until more
recently when being noted to have a slight rise in CA 15-3
to the 45 to 55 U/mL range. Brain MRI was stable with
no lesions.  18F-FDG PET/CT scan showed a solitary
hypermetabolic left hepatic lesion.
On the day of surgery, the preoperative clinical PET/CT
demonstrated a solitary hypermetabolic lesion in the left
lobe of the liver with a peak SUV of 17.6 (Figure 3). The
patient was subsequently taken to the operating room.
Intraoperative verification of tumor location within the
left hepatic lobe was performed by visualization, palpa-
tion, and handheld gamma probe detection. The patient
then underwent a left lateral segmentectomy of the liver
(Figure 4A). Post-resection, the surgical bed was again
evaluated by handheld gamma probe detection and was
found to have no activity above background. The entire
resected specimen was re-imaged by specimen PET/CT
and revealed a single hypermetabolic focus (Figure 4B).
Postoperatively, the patient recovered uneventfully in the
PACU. She was subsequently taken to the radiology
department and re-imaged with PET/CT scan, demon-
strating complete resection of the hypermetabolic hepatic
metastasis, and no residual hypermetabolic foci were
identified (Figure 4C).
Pathologic evaluation revealed a 3.7 cm carcinoma,
with negative surgical margins. The malignant cells were
Digital photograph of an axial section of a portion of the  specimen of the resected left breast tissue, but devoid of the  resected left axillary tissue (A) Figure 2
Digital photograph of an axial section of a portion of the 
specimen of the resected left breast tissue, but devoid of the 
resected left axillary tissue (A). Cross sectional specimen 
fused PET/CT images of the resected left breast and left axil-
lary dissection tissue revealing two hypermetabolic foci (B). 
Postoperative PET maximum intensity projection in the ante-
rior projection view of the chest demonstrating that the pri-
mary breast tumor and solitary axillary metastasis have been 
completely resected and that no residual hypermetabolic foci 
are demonstrated (C).World Journal of Surgical Oncology 2007, 5:143 http://www.wjso.com/content/5/1/143
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positive for cytokeratin 7 and Her2neu (by FISH) and
were negative for cytokeratin 20, ER, PR, BRST-2, and
chromogranin.
Discussion
It is well established that 18F-FDG PET imaging is a pow-
erful tool for assisting in the diagnosis as well as in the
staging and monitoring of therapy response for a variety
of neoplastic processes, including breast cancer [10-12].
One of the main limitations, as it applies to the current
use of PET imaging, is that our standard practice of preop-
erative image acquisition at the time of the original evalu-
ation of the cancer patient cannot realistically be
translated into real-time information that is available
within the operating room environment. Frequently, it
can be difficult for the oncologic surgeon to intraopera-
tively localize presumed abnormalities that were evident
on preoperative image acquisition taken at the time of the
initial work-up of the cancer patient. Such limitations can
result in the inability to detect occult disease and may lead
to incomplete tumor resection at the time of definitive
cancer surgery. This may ultimately be responsible for dis-
ease recurrence and impact negatively upon long-term
patient outcomes. Thus, allowing the oncologic surgeon
access to imaging and metabolic information intraopera-
tively, by using perioperative 18F-FDG PET/CT imaging
and intraoperative 18F-FDG gamma probe detection, has
the great potential to significantly improve overall success
of complete surgical resection and may ultimately impact
positively upon long-term patient outcomes.
Many studies have demonstrated the utility of 18F-FDG
PET in the staging of breast cancer [4-8,13]. Port et al stud-
ied 80 patients with high risk operable breast cancer, com-
paring conventional imaging staging (bone scan and CT
scan) with PET-assisted staging [6]. In this study, PET
localized metastatic disease that was not seen with con-
ventional imaging in 5% of patients. Conventional imag-
ing had a higher false positive rate than PET (17% versus
5%), resulting in additional unnecessary tests that were
ultimately negative. They concluded that PET was equally
sensitive, but more specific, than conventional imaging in
detecting occult disease and could better detect metastatic
disease, thus resulting in changes in treatment planning in
approximately 5% of patients.
Other studies have focused on the utility of 18F-FDG PET
in assessing axillary lymph node metastases. Kumar et al
concluded that 18F-FDG PET cannot replace histological
staging using sentinel lymph node biopsy in patients with
breast cancer, but has both a high specificity and high pos-
itive predictive value for the staging of the axilla in these
patients [7]. They determined that the positive predictive
value and accuracy of 18F-FDG PET for the detection of
axillary lymph node metastases were 89% and 72%,
respectively, for the 80 patients they studied. Unfortu-
nately, due to a false negative rate of 20% in detecting axil-
lary lymph node metastases, it has been concluded that
18F-FDG PET cannot replace sentinel node biopsy if the
PET scan images are negative within the axilla [4].
It has also been demonstrated that patients with a preop-
erative 18F-FDG PET scan showing axillary lymph nodes
Preoperative PET maximum intensity projection in the ante- rior projection view (A) and cross sectional fused PET/CT  images (B) Figure 3
Preoperative PET maximum intensity projection in the ante-
rior projection view (A) and cross sectional fused PET/CT 
images (B). The preoperative PET/CT scan revealed a solitary 
hypermetabolic focus in the left lobe of the liver.
Digital photograph of the resected liver tissue specimen (A)  and maximum intensity projection from the specimen PET  scan (B) Figure 4
Digital photograph of the resected liver tissue specimen (A) 
and maximum intensity projection from the specimen PET 
scan (B). Postoperative PET maximum intensity projection in 
the anterior projection view of the lower chest and upper 
abdomen demonstrating that there is no longer a hypermeta-
bolic focus in the region of the liver (C).World Journal of Surgical Oncology 2007, 5:143 http://www.wjso.com/content/5/1/143
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that have an SUV greater than 2.3 were more likely to have
axillary metastases, thus obviating the need for sentinel
lymph node biopsy or needle biopsy to diagnose axillary
lymph node involvement [5]. In this setting, Chung et al
advocate that the oncologic surgeon can proceed directly
to an axillary lymph node dissection to accurately assess
the number of axillary lymph nodes involved, eradicate
axillary disease, and possibly provide a potential survival
benefit [5].
In addition to the usefulness of 18F-FDG in the preopera-
tive localization of all sites of tumor, 18F-FDG has also
been shown to be useful for localizing colorectal tumor
intraoperatively using handheld gamma probes [14-19].
Handheld gamma probes have been shown to be capable
of detecting the 511 keV photons emitted from positron
annihilation [20-22]. Desai et al injected 14 colorectal
cancer patients with 18F-FDG prior to their surgical proce-
dure [15]. The handheld gamma probe correctly identi-
fied a single tumor focus or multiple tumor foci in 13/14
patients (3 standard deviations above counts obtained
from normal tissues). This study demonstrated, for the
first time, that tumors identified from preoperative whole-
body PET scans can be localized during surgery utilizing
18F-FDG handheld gamma probe detection. Additionally,
Higashi et al have investigated the optimal timing for
intraoperative 18F-FDG handheld gamma probe detection
of tumors using phantom and patient data and deter-
mined that detection was best at a duration of time of
approximately one to three hours after the injection of
18F-FDG [23]. Tumor to normal tissue and tumor to con-
tralateral tissue ratios demonstrated lowest standard devi-
ations at one to three hours compared to later times and
there was no significant tumor to normal or tumor to
contralateral tissue ratio when probing at later times [23].
Despite the fact that 18F-FDG PET is accepted as a useful
tool in the preoperative evaluation and staging of appro-
priately selected breast cancer patients and despite the fact
that there is currently some data available on the utiliza-
tion of the handheld gamma probe for intraoperatively
detecting various 18F-FDG positive malignancies [14-
21,24-27], there has been very little clinical investigation
into specifically utilizing a combined approach of periop-
erative  18F-FDG PET/CT technology and intraoperative
18F-FDG gamma probe detection. Thus, having available
such an innovative combined imaging/detection technol-
ogy in the perioperative and intraoperative arena has the
potential for improving the oncologic surgeons' success
rates in achieving an optimal and/or complete resection
of the tumor burden. The current report, for the first time,
comprehensively describes the feasibility and usefulness
of such an innovative combined strategy of perioperative
18F-FDG PET/CT imaging and intraoperative 18F-FDG
gamma probe detection for tumor localization and
verification of resection in two distinctive cases of
potentially resectable metastatic breast cancer. Such an
innovative approach clearly provides the oncologic sur-
geon with real-time access to metabolic and morphologic
tumor information that may better lead to complete
tumor resection and avoidance of missed occult disease.
In the two patients that were studied in this paper, 18F-
FDG PET/CT accurately localized all tumor sites. Acquir-
ing the PET/CT scan immediately prior to the surgical pro-
cedure allowed for visual verification of tumor location
prior to surgery. The 18F-FDG dose used for the preopera-
tive clinical PET/CT scan was adequate for the intraopera-
tive localization of all hypermetabolic tumor foci by the
handheld gamma probe. The handheld gamma probe
results from the tumor and surrounding tissue correlated
well with the PET scan findings. The intraoperative speci-
men PET/CT and postoperative PET/CT of the patients
were highly useful for verifying complete tumor resection.
With the advent of consideration of utilizing 18F-FDG for
intraoperative gamma probe detection in oncologic sur-
gery, it is not unexpected that increasing questions and
concerns will arise with regards to resultant occupational
radiation exposure to the operating surgeon and to the
involved perioperative personnel. To date, essentially no
published data is available that has specifically addressed
this particular issue. However, the current authors have
very recently published data on calculated theoretical
radiation doses encountered by the surgeon during
gamma probe surgery [16]. A theoretical maximum esti-
mated radiation dose of only 606 μGy (0.606 mGy)
would be incurred by a surgeon standing 0.152 meters (6
inches) from the 18F-FDG source for 5 hours. Such a radi-
ation dose is only a fraction of the annual occupational
limit of 50,000 μGy/year (50 mGy/year), thus potentially
allowing the surgeon to perform approximately 80 such
cases a year. Furthermore, a more comprehensive evalua-
tion of actual occupational radiation exposure to the
operating surgeon and to the involved perioperative per-
sonnel is currently being undertaken by the present
authors.
One of the limitations of the innovative techniques pre-
sented in this communication is the lack of specificity of
18F-FDG. It is well established that normal physiologic
uptake of 18F-FDG is demonstrated to varying degrees in
multiple normal tissues. It is also widely accepted that 18F-
FDG is excreted in the urine and therefore significant
activity is noted within the collecting systems of the kid-
neys as well as the bladder. These are recognized and
understood limitations of 18F-FDG PET imaging. How-
ever, utilizing the 3 sigma threshold for a gamma probe
with normal background activity coming from normal
surrounding tissues, as well as consideration being givenWorld Journal of Surgical Oncology 2007, 5:143 http://www.wjso.com/content/5/1/143
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to location of abnormal activity from the preoperative
PET/CT scan, some of these limitations can be overcome.
False positive findings on the PET/CT scan and conse-
quently false positive gamma probe investigation findings
should certainly be correlated with frozen section and
pathology verification. This study was designed to dem-
onstrate the feasibility of an innovative technique involv-
ing perioperative and intraoperative imaging and
intraoperative gamma probe utilization for assistance in
tumor localization and verification of resection.
Another limitation of 18F-FDG PET/CT scanning is the
110 minute half-life of 18F. This limitation is relavant to
postoperative PET/CT scanning, specimen PET/CT scan-
ning, and intraoperative gamma probe detection. By
increasing the scan time (10 minutes per bed position),
we have been able to generate high quality images on the
PET/CT scanner at times as far out as 9 to 10 hours post-
injection of the clinical dose of 18F-FDG.
The limitations of PET scanning as well as the limitations
associated with the specificity of 18F-FDG as a tumor tracer
are acknowledged. Further development of more specific
radiotracers may compensate for many of these limita-
tions. However, addition of these new and innovative
technologies to the operative arena have significant
potential for improving successful resection of tumors
with negative margins and improving long term patient
outcomes. Further explorations on the feasibility of these
techniques as well as validation with pathology correla-
tion and patient outcomes will be helpful in assessing the
benefit of these techniques.
Conclusion
This innovative combined technology of perioperative
18F-FDG PET/CT imaging and intraoperative 18F-FDG
gamma probe detection demonstrates great promise for
providing real-time feedback to the oncologic surgeon for
successful complete surgical resection of all sites of tumor.
The future potential for a more widespread application of
this innovative technology to the surgical oncology arena
lies in such applications as verification of primary tumor
site resection, margin assessment, regional lymph node
assessment, and recognition of sites of occult disease. All
these potential applications have great promise for posi-
tively impacting on long-term patient outcomes.
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